These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35346571)

  • 1. Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
    Fukuokaya W; Kimura T; Komura K; Uchimoto T; Nishimura K; Yanagisawa T; Imai Y; Iwatani K; Ito K; Urabe F; Tsuzuki S; Kimura S; Terada N; Mukai S; Oyama Y; Abe H; Kamoto T; Azuma H; Miki J; Egawa S
    Urol Oncol; 2022 Jul; 40(7):346.e1-346.e8. PubMed ID: 35346571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
    Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
    Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
    Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
    Sekito T; Bekku K; Katayama S; Watanabe T; Tsuboi I; Yoshinaga K; Maruyama Y; Yamanoi T; Kawada T; Tominaga Y; Sadahira T; Iwata T; Nishimura S; Kusumi N; Edamura K; Kobayashi T; Kurose K; Ichikawa T; Miyaji Y; Wada K; Kobayashi Y; Araki M
    Clin Genitourin Cancer; 2024 Aug; 22(4):102097. PubMed ID: 38763123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
    Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
    Fukuokaya W; Yanagisawa T; Hashimoto M; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Miki J; Oyama Y; Abe H; Kimura T
    Cancer Immunol Immunother; 2023 Apr; 72(4):841-849. PubMed ID: 36102985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
    Iida K; Naiki T; Etani T; Nagai T; Sugiyama Y; Isobe T; Aoki M; Nozaki S; Noda Y; Shimizu N; Tomiyama N; Gonda M; Kamiya H; Kubota H; Nakane A; Ando R; Kawai N; Yasui T
    Sci Rep; 2024 Jan; 14(1):2520. PubMed ID: 38291115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
    Tomisaki I; Harada M; Sakano S; Terado M; Hamasuna R; Harada S; Matsumoto H; Akasaka S; Nagata Y; Minato A; Harada KI; Fujimoto N
    Int J Urol; 2023 Sep; 30(9):738-745. PubMed ID: 36693764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
    Fiala O; Buti S; Takeshita H; Okada Y; Massari F; Palacios GA; Dionese M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Quiroga MNG; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Cattrini C; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchenhorn D; Santini D; Manneh R; Bisonni R; Zakopoulou R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Sorgentoni G; Battelli N; Porta C; Bellmunt J; Santoni M
    Cancer Immunol Immunother; 2023 Nov; 72(11):3665-3682. PubMed ID: 37676282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
    Okuyama Y; Hatakeyama S; Numakura K; Narita T; Tanaka T; Miura Y; Sasaki D; Noro D; Tokui N; Okamoto T; Yamamoto H; Narita S; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
    BJUI Compass; 2022 Mar; 3(2):154-161. PubMed ID: 35474728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
    Clin Cancer Res; 2020 Oct; 26(20):5487-5493. PubMed ID: 32933995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    Cancer Immunol Immunother; 2022 Jan; 71(1):229-236. PubMed ID: 34100985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
    Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
    Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
    Taguchi S; Kawai T; Buti S; Bersanelli M; Uemura Y; Kishitani K; Miyakawa J; Sugimoto K; Nakamura Y; Niimi F; Kaneko T; Kamei J; Obinata D; Yamaguchi K; Kakutani S; Kanazawa K; Sugihara Y; Tokunaga M; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Fujimura T; Fukuhara H; Nakagawa T; Takahashi S; Kume H
    Immunotherapy; 2023 Aug; 15(11):827-837. PubMed ID: 37191002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
    Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
    Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.
    Ruiz-Bañobre J; Molina-Díaz A; Fernández-Calvo O; Fernández-Núñez N; Medina-Colmenero A; Santomé L; Lázaro-Quintela M; Mateos-González M; García-Cid N; López-López R; Vázquez S; Anido-Herranz U
    ESMO Open; 2021 Apr; 6(2):100090. PubMed ID: 33740735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
    Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Ono Y; Tagawa T; Okamoto T; Hamatake M; Okamoto I; Mori M
    PLoS One; 2022; 17(2):e0263247. PubMed ID: 35130287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    Target Oncol; 2021 Mar; 16(2):189-196. PubMed ID: 33400096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
    Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.